Omeros Company Profile (NASDAQ:OMER)

About Omeros

Omeros logoOmeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: OMER
  • CUSIP: 68214310
Key Metrics:
  • Previous Close: $11.51
  • 50 Day Moving Average: $10.10
  • 200 Day Moving Average: $10.49
  • 52-Week Range: $7.20 - $16.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.98
  • P/E Growth: -0.08
  • Market Cap: $495.67M
  • Outstanding Shares: 42,915,000
  • Beta: 3.16
  • Net Margins: -189.16%
  • Return on Assets: -104.29%
  • Debt-to-Equity Ratio: -3.09%
  • Current Ratio: 3.78%
  • Quick Ratio: 3.69%
Additional Links:
Companies Related to Omeros:

Analyst Ratings

Consensus Ratings for Omeros (NASDAQ:OMER) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.23 (187.73% upside)

Analysts' Ratings History for Omeros (NASDAQ:OMER)
DateFirmActionRatingPrice TargetDetails
2/21/2017WedbushReiterated RatingOutperform$47.00View Rating Details
11/17/2016WBB SecuritiesReiterated RatingBuy$75.00View Rating Details
11/11/2016Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details
11/10/2016FBR & CoReiterated RatingBuyView Rating Details
11/10/2016Needham & Company LLCLower Price TargetBuy$28.00 -> $24.00View Rating Details
11/2/2016Maxim GroupSet Price TargetBuy$19.00View Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63View Rating Details
8/19/2015Roth CapitalReiterated RatingBuy$38.00View Rating Details
8/18/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$38.00View Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Omeros (NASDAQ:OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Omeros (NASDAQ:OMER)
Current Year EPS Consensus Estimate: $-1.71 EPS
Next Year EPS Consensus Estimate: $-0.89 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.52)($0.42)($0.47)
Q2 20163($0.52)($0.31)($0.43)
Q3 20163($0.31)($0.22)($0.27)
Q4 20163($0.54)($0.12)($0.38)
Q1 20172($0.36)($0.36)($0.36)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.29)($0.21)($0.25)
Q4 20172($0.28)($0.11)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for Omeros (NASDAQ:OMER)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Omeros (NASDAQ:OMER)
Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 47.94%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.84View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.00View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.40View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.60View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Omeros (NASDAQ:OMER)
DateHeadline logoNoteworthy Friday Option Activity: SPWR, W, OMER (NASDAQ:OMER) - February 18 at 11:47 AM
News IconShares in Focus: Omeros Corporation (NASDAQ:OMER) - Piedmont Register (NASDAQ:OMER) - February 17 at 4:42 PM logoAlexion Needs New Bets (NASDAQ:OMER) - February 16 at 6:36 PM
News IconChecking the Levels on Shares of Omeros Corporation (NASDAQ:OMER) - Sherwood Daily (NASDAQ:OMER) - February 16 at 6:36 PM logoAppetite (Eating) Disorders Market Share, Size, Growth & Forecast 2024 Illuminated by New Report (NASDAQ:OMER) - February 15 at 3:29 AM
News IconIndicators in Focus on Omeros Corporation (NASDAQ:OMER) - Piedmont Register (NASDAQ:OMER) - February 14 at 10:28 PM logoOmeros Corporation (NASDAQ:OMER) EPS Target At $-0.185 - Investor Newswire (NASDAQ:OMER) - February 14 at 1:16 AM
News IconShares in Review: Omeros Corporation (OMER) - Providence Standard (NASDAQ:OMER) - February 10 at 1:12 AM logoOmeros Shorts Are Feeling The Heat (NASDAQ:OMER) - February 9 at 8:09 PM
News IconNews Impact Score Of Omeros Corporation (NASDAQ:OMER) At 50 - Stock Observer (NASDAQ:OMER) - February 9 at 12:57 AM logoOmeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : February 8, 2017 (NASDAQ:OMER) - February 8 at 7:56 PM
News IconBrain Disease Industry Survey 2017 Deep Market Research Report Analysis, Forecast and Outlook 2025 (NASDAQ:OMER) - February 7 at 8:06 PM logoBrain Disease Market : The report includes drivers and restraints and their impact on the growth of the market (NASDAQ:OMER) - February 7 at 9:09 AM logoGraves Diseases - Pipeline Review, H2 2016 - Key Companies are Apitope International NV, Nova Therapeutics … (NASDAQ:OMER) - February 7 at 9:09 AM logoGraves Diseases - Pipeline Review, H2 2016 - Key Companies are Apitope International NV, Nova Therapeutics LLC, Novartis AG, Omeros Corp & Rodos BioTarget GmbH - Research and ... (NASDAQ:OMER) - February 7 at 9:09 AM
News IconStock Vacillating as Volatility Hits a High Point For Omeros Corporation (NASDAQ:OMER) - Wall Street Beacon (NASDAQ:OMER) - February 1 at 1:03 AM
News IconIngalls & Snyder LLC Has Upped Omeros Corp (OMER) Stake by $7.39 Million as Stock Price Declined (NASDAQ:OMER) - January 31 at 8:01 PM
News IconMarket Check: Narrowing in on Shares of Omeros Corporation (NASDAQ:OMER) - The Tribune (NASDAQ:OMER) - January 31 at 12:45 AM
News IconOmeros Corporation (NASDAQ:OMER) Quarterly EPS Projection At $-0.44 - Stock Observer (NASDAQ:OMER) - January 28 at 7:09 PM
News IconEarnings in Full Force, Analysts Take Aim at Omeros Corporation (NASDAQ:OMER) - Wall Street Beacon (NASDAQ:OMER) - January 28 at 7:09 PM
News IconTale of the Tape: Technical Recap for Omeros Corporation (OMER) - Rives Journal (NASDAQ:OMER) - January 28 at 7:09 PM
News IconOpium (Opioid) Addiction - Pipeline Review, H2 2016 - New Market Study Published (NASDAQ:OMER) - January 25 at 11:09 PM
News IconCCI Focus on Shares of Omeros Corporation (OMER) - Sherwood Daily (NASDAQ:OMER) - January 25 at 12:50 AM
News IconConsensus Take: Omeros Corporation (NASDAQ:OMER) Earnings & Ratings Watch - Aiken Advocate (NASDAQ:OMER) - January 25 at 12:50 AM
News IconNews Impact Score Of Omeros Corporation (NASDAQ:OMER) At 0 - Stock Observer (NASDAQ:OMER) - January 24 at 7:48 PM
News IconIntracameral phenylephrine/ketorolac superior to intracameral epinephrine (NASDAQ:OMER) - January 24 at 9:01 AM
News IconOmeros Corp OMER Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:OMER) - January 24 at 9:01 AM
News IconRecent research: Restless legs syndrome - pipeline review, H2 2016 (NASDAQ:OMER) - January 23 at 9:42 AM
News IconSignal Watch: Checking the Numbers for Omeros Corporation (OMER) - Rives Journal (NASDAQ:OMER) - January 20 at 7:49 PM logoETFs with exposure to Omeros Corp. : January 19, 2017 (NASDAQ:OMER) - January 19 at 11:39 PM
News IconConsensus Take: Omeros Corporation (NASDAQ:OMER) Earnings ... - Aiken Advocate (NASDAQ:OMER) - January 18 at 12:25 AM
News IconEPS Of Omeros Corporation (NASDAQ:OMER) At $-0.44 - Stock Observer (NASDAQ:OMER) - January 12 at 7:39 PM
News IconWill The Needle Move For Omeros Corporation (NASDAQ:OMER) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:OMER) - January 12 at 7:39 PM
News IconNews Impact Score Of Omeros Corporation (NASDAQ:OMER) Set At 0 - Stock Observer (NASDAQ:OMER) - January 10 at 7:54 PM
News IconReady for an Upsurge? Analysts Chime in on Omeros Corporation (NASDAQ:OMER) - Prospect Journal (NASDAQ:OMER) - January 10 at 12:45 AM logoAnalyst Activity – Wedbush Reiterates Outperform on Omeros Corporation (NASDAQ:OMER) - Market Exclusive (NASDAQ:OMER) - January 7 at 11:16 PM
News IconNicotine Addiction -under Development by Companies, H2 2016 (NASDAQ:OMER) - January 6 at 7:43 PM logoAnalyst Activity – Wedbush Reiterates Outperform on Omeros Corporation (NASDAQ:OMER) (NASDAQ:OMER) - January 5 at 11:14 PM logoSentiments And Ratings Alert: Omeros Corporation (NASDAQ:OMER) - Investor Newswire (NASDAQ:OMER) - January 5 at 5:54 AM
News IconCRG Recommits to Healthcare Sector with Third Credit Fund (NASDAQ:OMER) - January 4 at 7:50 PM
News IconOmeros Corporation (NASDAQ:OMER) News Impact Score At 0 - Stock Observer (NASDAQ:OMER) - January 4 at 6:46 AM
News IconOmeros Corporation (OMER) Valuation According To Analysts - UK ... - UK Market News (NASDAQ:OMER) - January 4 at 6:46 AM logoETFs with exposure to Omeros Corp. : January 3, 2017 (NASDAQ:OMER) - January 3 at 11:27 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Omeros Corporation (NASDAQ:OMER) - Prospect Journal (NASDAQ:OMER) - January 3 at 10:26 AM
News IconNext Weeks Broker Price Targets For MGIC Investment Corporation (NYSE:MTG) (NASDAQ:OMER) - December 29 at 9:21 AM logoOmeros Corp. – Value Analysis (NASDAQ:OMER) : December 23, 2016 (NASDAQ:OMER) - December 23 at 7:11 PM logoOmeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : December 22, 2016 (NASDAQ:OMER) - December 22 at 8:10 AM
News IconMarket Focus: Checking Up on Shares of Omeros Corporation (NASDAQ:OMER) - OIB News (NASDAQ:OMER) - December 21 at 7:50 PM logoOmeros Corporation (NASDAQ:OMER) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:OMER) - December 21 at 7:50 PM
News IconUpdate on Valuation Formula's For Omeros Corporation (NASDAQ:OMER) - Marion Business Daily (NASDAQ:OMER) - December 20 at 1:19 PM


What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Where is Omeros' stock going? Where will Omeros' stock price be in 2017?

6 analysts have issued 1 year price targets for Omeros' shares. Their forecasts range from $8.63 to $75.00. On average, they anticipate Omeros' stock price to reach $33.23 in the next twelve months.

When will Omeros announce their earnings?

Omeros is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:

  • According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (1/4/2017)

  • Maxim Group analysts commented, "Omeros announced a debt financing for $20M (effective on 5/18/16) from its existing credit facility with Oxford Finance and East West Bank." (5/19/2016)

Who owns Omeros stock?

Omeros' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Cpcm LLC (2.99%), State Street Corp (2.20%), Opaleye Management Inc. (0.62%), RTW Investments LP (0.60%), Allianz Asset Management AG (0.27%) and Baird Financial Group Inc. (0.22%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Peter A Md Demopulos and Thomas J Cable.

Who sold Omeros stock? Who is selling Omeros stock?

Omeros' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP and Allianz Asset Management AG. Company insiders that have sold Omeros stock in the last year include Gregory A Md Demopulos, Marcia S Kelbon and Thomas J Cable.

Who bought Omeros stock? Who is buying Omeros stock?

Omeros' stock was bought by a variety of institutional investors in the last quarter, including Cpcm LLC, Opaleye Management Inc., Rubric Capital Management LP, State Street Corp, Dynamic Technology Lab Private Ltd, Baird Financial Group Inc., Raymond James Financial Services Advisors Inc. and First Allied Advisory Services Inc..

How do I buy Omeros stock?

Shares of Omeros can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Omeros stock cost?

One share of Omeros stock can currently be purchased for approximately $11.55.

Omeros (NASDAQ:OMER) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Earnings History Chart

Earnings by Quarter for Omeros (NASDAQ:OMER)

Dividend History Chart

Dividend Payments by Quarter for Omeros (NASDAQ:OMER)

Last Updated on 2/25/2017 by Staff